Genfit S.A. GNFT NASDAQ · Healthcare · France
$7.82 -6.18% -$0.52
Summary
26 / 100 · Bulios Score
What speaks for it
- It earns 12 EUR a year on every 100 EUR of invested capital.
- It could repay all its net debt from 1.3 years of operating profit.
What to watch
- Revenue fell by 13% a year over the last 3 years.
- It reports a profit, yet spends more cash than it brings in.
- It passes only 2 of the 9 points of the Piotroski financial health test.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveIs it growing?
It is shrinkingRevenue (EUR)
- Analyst estimate
Revenue grew by 17% a year over 5 years. Over the last 3 years it fell by 13% a year.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
YesIt holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 6
- Hold 0
- Sell 1
No analyst has published a price target.
86% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
This revenue breakdown is on the way.
By region
This revenue breakdown is on the way.